U.S. Supreme Court declines bid by Teva to hear ‘skinny labeling’ case with implications for generic drug access

“I’m shocked,” said S. Sean Tu, a law professor at West Virginia University, who was one of dozens of academics who filed a brief urging the Supreme Court to hear the case. “A lot of generic companies use this pathway to get on the market. If we don’t have that, it could end up costing consumers untold dollars. This is not what Congress intended.”